drugset / Trial / NCT04859439
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects with normal renal function.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2021-11-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DBPR108 | Small molecule | 100 mg | Oral |